Diana Ernst, RPh, Author at Rheumatology Advisor

Diana Ernst, RPh

All articles by Diana Ernst, RPh

First Sclerostin Inhibitor Approved for Postmenopausal Women at High Risk for Fracture

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.

Next post in Osteoarthritis